The NHLBI LAM Registry: Prognostic physiological and radiological biomarkers emerge from a 15-year prospective longitudinal analysis.

CONCLUSIONS: The median transplant-free survival in patients with LAM is greater than 20 years. Menopausal status as well as structural and physiological markers of disease severity significantly affect the rate of decline of FEV1 and progression to death or lung transplantation in LAM. PMID: 29940164 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29940164?dopt=Abstract

Source: Chest - June 22, 2018 Category: Respiratory Medicine Authors: Gupta N, Lee HS, Ryu JH, Taveira-DaSilva AM, Beck GJ, Lee JC, McCarthy K, Finlay GA, Brown KK, Ruoss SJ, Avila NA, Moss J, McCormack FX, NHLBI LAM Registry Group Tags: Chest Source Type: research